Barcelona [Spain]: With over 2 million new cases each year, colon cancer is the third most prevalent disease in the world. The majority of patients receive their diagnosis while the tumour is still in the colon or rectum.
These tumours are surgically removed, and chemotherapy is frequently used to treat them in an effort to stop a relapse. Between 20 per cent and 35 per cent of individuals, however, experience cancer coming back as metastases in other crucial organs. These are brought on by tumour cells that are still present, but are hidden at the time of surgery. Nearly all cancers, including colon cancer, are most commonly fatal due to metastases. The majority of colorectal cancer research has concentrated on the main condition. Additionally, there have been significant developments in recent years regarding how to identify metastatic disease after it has already manifested.
But up until recently, it had been impossible to investigate this small group of disseminated tumour cells since they are undetectable by clinical diagnostic methods. Because of this ignorance, there aren't many medications that can effectively treat the remaining disease and stop it from spreading again, which has a bad prognosis.
Scientists at IRB Barcelona, led by Dr Eduard Batlle, ICREA researcher and group leader within the cancer CIBER network (CIBERONC), have for the first time identified residual tumour cells hidden in the liver and lung and have described how they evolve to give rise to the appearance of metastases in these organs.
"Understanding and avoiding the phenomenon of relapse after surgery is an unresolved medical need. After many years investigating cancer">colon cancer, we have taken the first step to prevent metastases in patients who present with localized disease," explains Dr Eduard Batlle, head of the Colorectal Cancer Laboratory at IRB Barcelona.
How does colon cancer recurrence occur? A novel experimental mouse model that mimics the process patients go through when they relapse has been created by scientists. The typical progression of this is the diagnosis, curative surgery, and relapse. In addition, they have developed a method that enables the isolation of a minor portion of liver-hidden disseminated tumour cells.
"The model, which is very similar to the progression of metastatic colon cancer in patients, has allowed us to describe the dynamics of residual disease in detail. We have studied metastases ranging from the micro-scale of 3 or 4 cells to medium-sized or even larger ones and have detailed how each of them evolves during the progression of the disease," comments Dr Adria Canellas-Socias, a researcher at the laboratory headed by Dr Batlle and first author of the study.
Also read: Cancer is the second leading cause of death says WHO: National Cancer Awareness Day 2022
Defining the High Relapse Cells: Colon cancer is made up of various tumour cell types, each of which performs a specific job as the disease progresses, as scientists have long known. Colon cancer is caused by a variety of cell types, and researchers led by Dr Batlle have identified a group of these cells as HRCs (High Relapse Cells). These cells don't contribute to the underlying tumour's growth and proliferate infrequently. However, HRC clusters have the capacity to separate from the primary tumour, migrate to the liver, and stay concealed for some time after surgery. Researchers have been able to confirm the existence of these identical cells in people who are most at risk of relapse following treatment in samples from colon cancer patients.
Additionally, scientists have demonstrated that eradicating these cells by genetic methods is sufficient to halt metastasis, as demonstrated by the fact that animals with colon cancer do not recur after the excision of the primary tumour. Additionally, Dr Batlle's team has created a therapy plan to specifically eliminate any remaining disease and stop it from returning. They have shown that immunotherapy before surgery can eradicate early-stage metastases that are not yet obvious.
"Our discovery reveals how the group of tumour cells responsible for relapse behaves and also the genes that define them. In addition, it represents a proof of concept that paves the way for the development of new therapies, specifically aimed at eliminating residual disease, as well as new diagnostic tools to identify those patients at the greatest risk of relapse. Finally, our study points to the need for a revision of the clinical guidelines in the treatment of this type of cancer because, in many cases, it would be advisable to prescribe immunotherapy before surgery," concludes Dr Batlle.
New research directions may be developed in light of these findings. In order to thwart this process and stop the growth of metastases, Dr Batlle's lab is now concentrating on understanding when HRCs that have entered the liver become "activated" to regenerate a tumour. They are also trying to figure out what influences how these cells look and why different patients have different numbers of these cells. (ANI)
(This story has not been edited by ETV Bharat and is auto-generated from a syndicated feed.)
